Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Trimetazidine hydrochloride sustained-release tablet

A technology of trimetazidine hydrochloride and sustained-release tablets, which is applied in the direction of drug combination, cardiovascular system diseases, organic active ingredients, etc., can solve the problems of cumbersome preparation process steps, incomplete release, and unfavorable industrial production, and achieve the goal of preparing The effect of simple process, low production cost, and stable dissolution and release properties

Active Publication Date: 2019-02-12
BEIJING WINSUNNY PHARMA CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the composition has a long release time, about 75% of the drug is released in 16 hours, and the release is not complete
[0009] Patent CN1994280A describes the preparation of trimetazidine hydrochloride pellets by centrifugal granulation or extrusion spheronization, and the sustained release effect is achieved after fluidized bed coating. This preparation process is cumbersome and unfavorable for industrial production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Trimetazidine hydrochloride sustained-release tablet
  • Trimetazidine hydrochloride sustained-release tablet
  • Trimetazidine hydrochloride sustained-release tablet

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028]

[0029] Preparation:

[0030] A. trimetazidine hydrochloride, calcium hydrogen phosphate and povidone are mixed homogeneously to obtain a mixture;

[0031] b. Wet granulate the above mixture, and granulate to obtain drug granules;

[0032] c. Mix the above drug granules with hypromellose and zein evenly, and press into tablets.

Embodiment 2

[0034]

[0035] Preparation:

[0036] a. mixing trimetazidine hydrochloride, microcrystalline cellulose, dextrin and sodium carboxymethyl cellulose to obtain a mixture;

[0037] b. Wet granulate the above mixture, and granulate to obtain drug granules;

[0038] c. Mix the above drug granules with hypromellose and zein evenly, and press into tablets.

Embodiment 3

[0040]

[0041] Preparation:

[0042] a. mixing trimetazidine hydrochloride, pregelatinized starch and povidone evenly to obtain a mixture;

[0043] b. Wet granulate the above mixture, and granulate to obtain drug granules;

[0044] c. Mix the above drug granules with hypromellose, corn gluten, magnesium stearate and silicon dioxide evenly, and press into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
solubility (mass)aaaaaaaaaa
hardnessaaaaaaaaaa
Login to View More

Abstract

The invention relates to a trimetazidine hydrochloride sustained-release tablet. The trimetazidine hydrochloride sustained-release tablet is specifically prepared from trimetazidine hydrochloride, a framework material, a thinner and an adhesive, wherein the framework material is a mixture of hydroxypropyl methyl cellulose and zein. The trimetazidine hydrochloride sustained-release tablet has the advantages that by using the hydroxypropyl methyl cellulose and the zein as the framework material, the burst release effect in the early period of trimetazidine hydrochloride is overcime; the in-vitrorelease of the obtained sustained-release tablet is free from the influence by the pH (potential of hydrogen) environment; the release degree in 8 hours is greater than 80%; the release curve is uniform with the release curve of a market product; the trimetazidine hydrochloride sustained-release tablet is suitable for industrialized large-scale production.

Description

technical field [0001] The invention relates to a sustained-release preparation for treating angina pectoris, in particular trimetazidine hydrochloride sustained-release tablet, and a preparation method of the sustained-release tablet. Background technique [0002] Angina pectoris is a common cardiovascular disease, which is caused by coronary artery atherosclerosis and stenosis, coronary artery insufficiency, temporary myocardial ischemia and hypoxia, and a group of comprehensive symptoms with precordial pain as the main clinical manifestation. It is a kind of coronary heart disease with the highest incidence rate, which seriously threatens the health and life of human beings. It is mainly divided into stable angina and unstable angina. Angina pectoris can occur at any time in 24 hours, but most of them are from early morning to morning, and variant angina pectoris often occurs regularly at night. Therefore, it is required that the therapeutic drug can maintain an effecti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K47/38A61K31/495A61P9/10
CPCA61K9/0002A61K9/2054A61K9/2063A61K31/495
Inventor 黄玉锋张英杰杨文涛彭小玲杨西邈耿玉先产运霞
Owner BEIJING WINSUNNY PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products